Entera Bio shares Phase 2 EB613 bone density data at ASBMR meeting
Entera Bio Ltd. (NASDAQ: ENTX) presented post-hoc Phase 2 data and a Phase 3 study design for its oral osteoporosis ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)

